Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET‑amplified patient‑derived gastric cancer xenografts

Liu,Kai; Song,Xilin; Zhu,Meirong; Ma,Heng

doi:10.3892/ol.2015.3601

Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET‑amplified patient‑derived gastric cancer xenografts

Authors:
- Kai Liu
- Xilin Song
- Meirong Zhu
- Heng Ma
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Shandong Tumor Hospital, Jinan, Shandong 250117, P.R. China, Intensive Care Unit, Jinan Central Hospital, Jinan, Shandong 250013, P.R. China
Published online on: August 12, 2015 https://doi.org/10.3892/ol.2015.3601
Pages: 2003-2008
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is one of the most malignant diseases and one of the leading causes of cancer‑associated mortality worldwide. Although advances have been made in surgical techniques, perioperative management and the combined use of surgery with chemotherapy and/or radiotherapy, patients with advanced stage gastric cancer continue to face poor outcomes. Furthermore, it was reported that MET gene amplification and overexpression predicted the sensitivity to MET inhibitors in gastric cancer. However, the identification of drug‑resistant tumors has encouraged the pre‑emptive elucidation of the possible mechanisms of clinical resistance. The current study assessed a number of patient‑derived gastric cancer models with MET amplification and overexpression, including CNGAS028. The tumor tissues were subjected to microarray analysis (using single nucleotide polymorphism 6.0 and human genome U133 arrays) followed by western blotting. The results demonstrated that CNGAS028 xenograft tumors did not respond to treatment with a selective MET inhibitor. Additional analysis indicated that FGFR2 overexpression contributed to the resistance to MET inhibitors. Furthermore, treatment with a combination of fibroblast growth factor receptor 2 and MET inhibitors inhibited the growth of CNGAS028 xenograft tumors in vivo. In conclusion, the current results aid in understanding the mechanism of inherent resistance to selective MET inhibitors as well as provide important information for patient selection and clinical treatment strategies.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
2	Camargo MC, Anderson WF, King JB, Correa P, Thomas CC, Rosenberg PS, et al: Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut. 60:1644–1649. 2011. View Article : Google Scholar : PubMed/NCBI
3	Yamashita K, Sakuramoto S, Nemoto M, Shibata T, Mieno H, Katada N, et al: Trend in gastric cancer: 35 years of surgical experience in Japan. World J Gastroenterol. 17:3390–3397. 2011. View Article : Google Scholar : PubMed/NCBI
4	Meyer HJ and Wilke H: Treatment strategies in gastric cancer. Dtsch Arztebl Int. 108:698–705. 2011.PubMed/NCBI
5	Morishita A, Gong J and Masaki T: Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol. 20:4536–4545. 2014. View Article : Google Scholar : PubMed/NCBI
6	Maestrini E, Tamagnone L, Longati P, Cremona O, Gulisano M, Bione S, et al: A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci USA. 93:674–678. 1996. View Article : Google Scholar : PubMed/NCBI
7	Sattler M and Salgia R: c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy. Curr Oncol Rep. 9:102–108. 2007. View Article : Google Scholar : PubMed/NCBI
8	Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, et al: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 19:4947–4953. 2000. View Article : Google Scholar : PubMed/NCBI
9	Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 85:1894–1902. 1999. View Article : Google Scholar : PubMed/NCBI
10	Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K and Nakanishi I: Amplification of c-myc, K-sam and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest. 78:1143–1153. 1998.PubMed/NCBI
11	Sierra JR and Tsao MS: c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 3 Suppl:S21–S35. 2011. View Article : Google Scholar : PubMed/NCBI
12	Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, et al: MET amplification as a potential therapeutic target in gastric cancer. Oncotarget. 4:9–17. 2013.PubMed/NCBI
13	Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 6:3314–3322. 2007. View Article : Google Scholar : PubMed/NCBI
14	Abidoye O, Murukurthy N and Salgia R: Review of clinic trials: agents targeting c-Met. Rev Recent Clin Trials. 2:143–147. 2007. View Article : Google Scholar : PubMed/NCBI
15	Bengtsson H, Irizarry R, Carvalho B and Speed TP: Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics. 24:759–767. 2008. View Article : Google Scholar : PubMed/NCBI
16	Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, et al: Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PLoS One. 9:e921472014. View Article : Google Scholar : PubMed/NCBI
17	Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar : PubMed/NCBI
18	Oshima T and Masuda M: Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today. 42:313–327. 2012. View Article : Google Scholar : PubMed/NCBI
19	Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, et al: Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Invest New Drugs. 31:1158–1168. 2013. View Article : Google Scholar : PubMed/NCBI
20	Jänne PA, Gray N and Settleman J: Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 8:709–723. 2009. View Article : Google Scholar : PubMed/NCBI
21	SeboltLeopold JS and English JM: Mechanisms of drug inhibition of signalling molecules. Nature. 441:457–462. 2006. View Article : Google Scholar : PubMed/NCBI
22	Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, et al: Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer. 9:1212010. View Article : Google Scholar : PubMed/NCBI
23	Lee NV, Lira ME, Pavlicek A, Ye J, Buckman D, Bagrodia S, et al: A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells though [corrected] MAPK activation. PLoS One. 7:e396532012. View Article : Google Scholar : PubMed/NCBI